134 related articles for article (PubMed ID: 36587067)
21. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
[TBL] [Abstract][Full Text] [Related]
22. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.
Li X; Fujio M; Imamura M; Wu D; Vasan S; Wong CH; Ho DD; Tsuji M
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13010-5. PubMed ID: 20616071
[TBL] [Abstract][Full Text] [Related]
23. Crystal structures of bovine CD1d reveal altered αGalCer presentation and a restricted A' pocket unable to bind long-chain glycolipids.
Wang J; Guillaume J; Pauwels N; Van Calenbergh S; Van Rhijn I; Zajonc DM
PLoS One; 2012; 7(10):e47989. PubMed ID: 23110152
[TBL] [Abstract][Full Text] [Related]
24. Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d.
Yu KO; Im JS; Illarionov PA; Ndonye RM; Howell AR; Besra GS; Porcelli SA
J Immunol Methods; 2007 May; 323(1):11-23. PubMed ID: 17442335
[TBL] [Abstract][Full Text] [Related]
25. In contrast to other species, α-Galactosylceramide (α-GalCer) is not an immunostimulatory NKT cell agonist in horses.
Dossa RG; Alperin DC; Garzon D; Mealey RH; Brown WC; Jervis PJ; Besra GS; Cox LR; Hines SA
Dev Comp Immunol; 2015 Mar; 49(1):49-58. PubMed ID: 25445911
[TBL] [Abstract][Full Text] [Related]
26. Polar functional group-containing glycolipid CD1d ligands modulate cytokine-biasing responses and prevent experimental colitis.
Inuki S; Hirata N; Kashiwabara E; Kishi J; Aiba T; Teratani T; Nakamura W; Kojima Y; Maruyama T; Kanai T; Fujimoto Y
Sci Rep; 2020 Sep; 10(1):15766. PubMed ID: 32978421
[TBL] [Abstract][Full Text] [Related]
27. Optical Control of Cytokine Production Using Photoswitchable Galactosylceramides.
Hartrampf N; Seki T; Baumann A; Watson P; Vepřek NA; Hetzler BE; Hoffmann-Röder A; Tsuji M; Trauner D
Chemistry; 2020 Apr; 26(20):4476-4479. PubMed ID: 31788876
[TBL] [Abstract][Full Text] [Related]
28. Application of natural killer T cells in antitumor immunotherapy.
Hong C; Park SH
Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
[TBL] [Abstract][Full Text] [Related]
29. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
30. A molecular switch in mouse CD1d modulates natural killer T cell activation by α-galactosylsphingamides.
Wang J; Guillaume J; Janssens J; Remesh SG; Ying G; Bitra A; Van Calenbergh S; Zajonc DM
J Biol Chem; 2019 Sep; 294(39):14345-14356. PubMed ID: 31391251
[TBL] [Abstract][Full Text] [Related]
31. Structure and binding kinetics of three different human CD1d-alpha-galactosylceramide-specific T cell receptors.
Gadola SD; Koch M; Marles-Wright J; Lissin NM; Shepherd D; Matulis G; Harlos K; Villiger PM; Stuart DI; Jakobsen BK; Cerundolo V; Jones EY
J Exp Med; 2006 Mar; 203(3):699-710. PubMed ID: 16520393
[TBL] [Abstract][Full Text] [Related]
32. Leishmania donovani glycosphingolipid facilitates antigen presentation by inducing relocation of CD1d into lipid rafts in infected macrophages.
Karmakar S; Paul J; De T
Eur J Immunol; 2011 May; 41(5):1376-87. PubMed ID: 21425159
[TBL] [Abstract][Full Text] [Related]
33. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice.
Hong S; Scherer DC; Singh N; Mendiratta SK; Serizawa I; Koezuka Y; Van Kaer L
Immunol Rev; 1999 Jun; 169():31-44. PubMed ID: 10450506
[TBL] [Abstract][Full Text] [Related]
34. Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules.
Naidenko OV; Maher JK; Ernst WA; Sakai T; Modlin RL; Kronenberg M
J Exp Med; 1999 Oct; 190(8):1069-80. PubMed ID: 10523605
[TBL] [Abstract][Full Text] [Related]
35. Antigen specificity of semi-invariant CD1d-restricted T cell receptors: the best of both worlds?
Gumperz JE
Immunol Cell Biol; 2004 Jun; 82(3):285-94. PubMed ID: 15186260
[TBL] [Abstract][Full Text] [Related]
36. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells.
Wu D; Xing GW; Poles MA; Horowitz A; Kinjo Y; Sullivan B; Bodmer-Narkevitch V; Plettenburg O; Kronenberg M; Tsuji M; Ho DD; Wong CH
Proc Natl Acad Sci U S A; 2005 Feb; 102(5):1351-6. PubMed ID: 15665086
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and functional activity of labeled CD1d glycolipid agonists.
Jervis PJ; Polzella P; Wojno J; Jukes JP; Ghadbane H; Garcia Diaz YR; Besra GS; Cerundolo V; Cox LR
Bioconjug Chem; 2013 Apr; 24(4):586-94. PubMed ID: 23458425
[TBL] [Abstract][Full Text] [Related]
38. Role of invariant natural killer T (iNKT) cells in systemic lupus erythematosus.
Godó M; Sessler T; Hamar P
Curr Med Chem; 2008; 15(18):1778-87. PubMed ID: 18691038
[TBL] [Abstract][Full Text] [Related]
39. NKT-cell glycolipid agonist as adjuvant in synthetic vaccine.
Liu Z; Guo J
Carbohydr Res; 2017 Nov; 452():78-90. PubMed ID: 29080431
[TBL] [Abstract][Full Text] [Related]
40. The V alpha 14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex.
Sidobre S; Naidenko OV; Sim BC; Gascoigne NR; Garcia KC; Kronenberg M
J Immunol; 2002 Aug; 169(3):1340-8. PubMed ID: 12133957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
